1 / 31

Frederick Schnell Central Georgia Hematology Oncology Associates Macon, GA, USA

Kytril: a once-daily 5HT 3 receptor antagonist for control of chemotherapy-induced nausea and vomiting (CINV). Frederick Schnell Central Georgia Hematology Oncology Associates Macon, GA, USA. Nausea and vomiting significantly impact on patients’ quality of life 1.

china
Download Presentation

Frederick Schnell Central Georgia Hematology Oncology Associates Macon, GA, USA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Kytril: a once-daily 5HT3 receptor antagonist for control of chemotherapy-induced nausea and vomiting (CINV) Frederick Schnell Central Georgia Hematology Oncology AssociatesMacon, GA, USA

  2. Nausea and vomiting significantly impact on patients’ quality of life1 • Following chemotherapy†, nausea/vomiting scored by patients (n=80) using 5-day diary and 6-day Functional Living Index • Doctors and nurses (n=9) estimated frequency of acute and delayed nausea/vomiting †First-cycle moderately emetogenic chemotherapy 1. Grunberg. Proc Am Soc Clin Oncol 2002;21:250a (Abstract 996)

  3. Nausea and vomiting are rated as major side-effects of cancer therapy • Following the introduction of 5HT3 receptor antagonists, the rating of vomiting as a side-effect of chemotherapy has declined2,3 1. Coates et al. Eur J Cancer Clin Oncol 1983;19:203–8 2. de Boer-Dennert et al. Br J Cancer 1997;76:1055–61 3. Griffin et al. Ann Oncol 1996;7:189–95

  4. Pharmacologic control of vomiting • Pharmacologic prevention of vomiting is directed at blocking vomiting pathways before the administration of chemotherapy or radiotherapy treatments • Antiemetics may act via the:1 • vomiting center • chemoreceptor trigger zone • peripheral receptors (e.g. vagal afferent nerves) 1. Lindley, Blower. Am J Health-Syst Pharm 2000;57:1685–97

  5. Which antiemetic? • Commonly used agents include: • dopamine-receptor antagonists • corticosteroids • benzodiazepines • antihistamines • 5HT3-receptor antagonists • 5HT3-receptor antagonists are currently the ‘gold-standard’ antiemetic1–4 1. Gralla et al. J Clin Oncol 1999;17:2971–94 2. ASHP. Am J Health-Syst Pharm 1999;56:729–64 3. MASCC. Ann Oncol 1998;9:811–194. Koeller et al. Support Care Cancer 2002;10:514–22

  6. Optimizing antiemetic treatment • Awareness must be increased for: • current guidelines • evidence supporting guideline recommendations • incidence of and risk factors for nausea and vomiting • Antiemetic treatment must be individualized based on patients’ cytotoxic treatment and patient-specific factors

  7. Antiemetic guidelines • Differences exist in antiemetic guidelines • ASCO (American Society of Clinical Oncology) • MASCC (Multinational Association of Supportive Care in Cancer) • ASHP (American Society of Health-Systems Pharmacists) • Need easy-to-follow, comprehensive consensus guidelines • Need guidelines from radiation experts that address needs of radiation therapy patients

  8. Patients need less complicated, effective antiemetic therapy • The majority of cancer patients receiving radiotherapy are elderly out-patients • require fast-acting, long-duration oral antiemetics • Convenient once-daily oral dosing should: •  patient compliance •  control of nausea and vomiting •  patient quality of life

  9. Who is the ‘average’ cancer patient? • Cancer incidence and mortality greatest in elderly patients1 • ‘average’ patient >65 years2 • increased incidence of co-morbidities with aging (>3.6 in patients aged >65 years)3 • increased use of concomitant medications in patients >65 years (average medications=4.3 per person)4 1. Yancik, Ries. Hematol Oncol Clin North Am 2000;14:17–23 2. Yancik et al. J Clin Oncol 2001;19:1147–51 3. Yancik. Cancer 1997;80:1273–834. Jorgensen et al. Ann Pharmacother 2001;35:1004–9

  10. Chemotherapy- and radiation-induced emesis in the elderly • Elderly are more likely to suffer from chemotherapy and radiotherapy-induced toxicity1 • may have declining organ function • co-morbidities • concomitant medications2,3 • Consequences of nausea and vomiting can be exacerbated in elderly, mainly in patients with co-morbidities • dehydration in patients taking diuretics • exacerbation of cognitive problems • falls due to extra-pyramidal effects 1. Extermann et al. Hematol Oncol Clin North Am 2000;14:63–77 2. Jorgensen et al. Ann Pharmacother 2001;35:1004–9 3. Hanlon et al. Drugs Aging 2001

  11. Suboptimal antiemetic treatment in the elderly • Older patients may receive suboptimal antiemetic treatment because of: • gastrointestinal changes1 – decreased drug absorption • contraindications to corticosteroids (e.g. with hypertension, diabetes)2 • swallowing problems1,3 • noncompliance to oral therapies4 • possible cognitive impairment/confusion5 • Patients need a single drug intake per day 1. Orr, Chen. Am J Physiol Gastrointest Liver Physiol 2002;283:G1226–31 2. http://www.geriatricsyllabus.com/syllabus/main.jsp?cid=SCC-DER-4-2 3. Wilkinson, de Picciotto. S Afr J Commun Disord 1999;46:55–644. Lebovits et al. Cancer 1990;65:17–22; 5. Schroder et al. J Neural Transm Suppl 1998;54:51–9

  12. Which 5-HT3-receptor antagonist? • Kytril (granisetron) and ondansetron are currently indicated for CINV and radiotherapy-induced nausea and vomiting (RINV) • Differences exist between Kytril and ondansetron • underlying pharmacology • duration of efficacy • hepatic metabolism • dose adjustments in hepatically impaired patients • dosing regimens

  13. Drug-drug interactions • Kytril • not shown to induce or inhibit hepatic metabolism1 • only 5-HT3-receptor antagonist not linked to CYP2D6 genetic polymorphism1 • Ondansetron • known interactions • chemotherapeutic agents2 • antidepressants3 • antibiotics4,5 • analgesics6 1. Blower. Cancer J 2002;8:405–14; 2.Cagnoni et al. BMT 1999;24:1–4 3. Stanford, Stanford. J Psychopharmacol 1999;13:313–74. www.hivmedicationguide.com/Asp_bin/drug%20interactions.asp 5. www.anaesthetist.com/physiol/basics/metabol/cyp/o.htm 6. DeWitte et al. Anesth Analg 2001;92:1319–21

  14. Hepatic metabolism route • Kytril has not been shown to induce or inhibit hepatic metabolism1 *Minor 1. Bower. Cancer J 2002;8:405–14

  15. CYP2D6 polymorphism • Genetic polymorphism shown to affect cancer patients’ response to ondansetron and tropisetron therapy1 • Kytril not at risk for genetic polymorphism • genetic testing required to determine true risk Ultra-rapid metabolizers (enzyme induction)  Metabolism  Efficacy Poor metabolizers (enzyme inhibition)  Metabolism  Risk of AEs AE = adverse event 1. Kaiser et al. J Clin Oncol 2002;20:2805–11

  16. Cardiovascular warnings 1. Kytril (granisetron hydrochloride) Prescribing Information 2. Zofran (ondansetron hydrochloride) Prescribing Information 3. Anzemet (dolasetron mesylate) Prescribing information 4. Navoban (tropisetron) Prescribing Information

  17. Cardiotoxic effects of 5-HT3-receptor antagonists in healthy adults *p<0.05; **p<0.001 1. Boike et al. Am J Health-Syst Pharm 1997;54:1172–6 2. Benedict et al. J Cardiovasc Pharmacol 1996;28:53–9 3. Gray et al. Aviat Space Environ Med 1996;67:759–61 4. Hunt et al. J Clin Pharmacol 1995;35:705–12

  18. Dosing regimen: Kytril vs ondansetron • Ondansetron dosed 2–3 times daily • associated with swallowing problems when patients are nauseated • Once-daily Kytril dosing •  patient compliance •  patient quality of life

  19. Antiemetic therapy decisions • Therapy should depend on the unique needs of each patient: • age/health • co-morbidities • concomitant medications • Physicians need to be aware that differences exist between the available 5HT3-receptor antagonists

  20. Co-morbidity assessment Polypharmacy Drug–drug interactions Antiemetic selection that limits complications Reduced risk of toxicity Increased possibility of clinical efficacy A rational choice in the elderly

  21. Kytril vs ‘conventional’/older antiemetics • Double-blind, placebo-controlled trial • 30 patients undergoing single-fraction total body irradiation (7.5 Gy) received i.v.: • Kytril, 3 mg‡ • metoclopramide (20 mg), dexamethasone (6 mg/m2), lorazepam (2 mg), 1 hour prior to radiotherapy *No vomiting, no more than mild nausea and no rescue medication ‡Off-label dose in the USA 1. Prentice et al. Bone Marrow Transplant 1995;15:445–8

  22. Kytril is effective in patients refractory to ‘conventional’ antiemetics • Patients (n=15) refractory to treatment with dopamine-receptor antagonists were scheduled to receive Kytril, 1 mg/day p.o.,‡ 1–2 hours prior to further radiotherapy* • Results of Kytril therapy • complete remission of symptoms was observed in all patients on days 1–3 • immediate remission of nausea and vomiting was apparent in 33% of patients *Pelvic, lumboaortic ± iliac/splenic regions or mediastinum radiotherapy ‡Off-label dose 1. Krengli et al. Minerva Med 1996;87:605–8

  23. 100 Kytril p<0.002 tropisetron 88 80 p<0.05 82 74 60 Patients (%) 56 40 20 0 Vomiting Nausea Kytril vs tropisetron inpediatric cancer patients Aksoylar et al. Pediatr Hematol Oncol 2001;18:397–406

  24. Kytril is well tolerated – adverse events classed as mild and transient • Most frequently reported adverse events in clinical trials with Kytril 12 mg p.o. q.d. (n=1450); 2Metochlopramide/dexamethasone; phenothiazines/ dexamethasone; dexamethasone alone; prochlorperazine (n=599); 3(n=185) Kytril Prescribing Information, chemotherapy data

  25. RINV – a significant clinical problem • Over 80% of patients undergoing radiation of the upper torso will experience nausea and vomiting1 • Fractionated radiotherapy may involve up to 40 fractions over 6–8 weeks, resulting in prolonged symptoms of emesis2 • Uncontrolled nausea and vomiting may lead patients to delay or refuse future radiotherapy3 1. Danioux et al. Clin Radiol 1979;30:581–4 2. Feyer et al. Support Care Cancer 1998;6:253–60 3. Laszlo. In: Antiemetics and Cancer Chemotherapy, 1983:1–5

  26. p=0.003 50 Previouschemotherapy 45.6% 40 p=0.028 No chemotherapy 33.1% 30 Patients (%) 22.1% 20 15.1% 10 0 Vomiting Nausea Incidence of nausea and vomiting • Overall, 38.7% of patients experienced RINV • Previous chemotherapy increased risk of symptoms IGARR. Int J Radiat Oncol Biol Phys 1999;44:619–25

  27. 60 Upper hemibody (n=88) 50 Lower hemibody (n=101) 40 Patients experiencing nausea and vomiting (%) 30 20 10 0 0 60 90 120 150 180 210 240 270 300 330 360 Duration of symptoms (min) Duration of nausea and vomiting following radiotherapy • The symptoms of RINV can last several hours after therapy1 1. Danioux et al. Clin Radiol 1979;30:581–4

  28. Cisplatin Cyclophosphamide Carboplatin Kytril has a 24-hour duration of action • Kytril has ‘insurmountable’ 5HT3 receptor binding Kytril Ondansetron 9 hours 4 hours First-day early-onset emesis 2 1 0 First-day late-onset emesis Episodes/hour 0 4 8 12 16 20 24 Time after chemotherapy administration (hours)

  29. Addition of NK1 receptor antagonists improves efficacy of standard antiemetic regimen 1. Poli-Bigelli et al. Cancer 2003;97:3090–8 2. Hesketh et al. J Clin Oncol 2003;21:4112–9

  30. Kytril effective in combination with steroids and NK1 receptor antagonists • Combination of 5HT3 receptor antagonist and dexamethasone improves emetic control but delayed emesis still problematic • Addition of neurokinin 1 (NK1) receptor antagonists to 5HT3/dexamethasone extends emetic control • triple combination is now standard of care International anti-emetic guidelines† † Adapted from Multinational Association for Symptom Control in Cancer

  31. Conclusions • The 5-HT3-receptor antagonists are effective for the treatment of RINV • Kytril (granisetron) • effective in refractory patients • more effective than ‘conventional’ antiemetics • at least as effective as ondansetron • well tolerated • once-daily dosing • low risk for drug-drug interactions • no cardiovascular warning

More Related